DPP-4 Inhibitors (Gliptins)
Drug Safety Update
September 2012: Dipeptidylpeptidase-4 inhibitors - risk of pancreatitis
NICE Guidance (see also drug-specific links below)
NG28 Type 2 diabetes in adults: management, updated June 2022
Local Guidance
K&M Position Statement: DPP-4 inhibitors (gliptins) in the management of Type 2 Diabetes
See here for local Kent & Medway diabetes prescribing guidance
Linagliptin may be a good choice in patients with reduced renal function as no dosage reduction is necessary even in severe renal impairment. Other DDP-4 inhibitors may be used and all require dosage reduction according to creatinine clearance. Renal function should be measured before initiating treatment with a DPP-4 inhibitor and at regular intervals thereafter.
| Pack |
|---|
| 28 tablet |
| Pack |
|---|
| 28 tablet |
| Pack |
|---|
| 100 tablet |
| 28 tablet |
- On Formulary Preferred
- On Formulary Second Line
- On Formulary Third Line
- Specialist Initiation
- Secondary Care Only
- Not Approved for Formulary